Gilead Sciences, Inc. (GILD)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $bn | 25 | 27 | 27 | 27 | 29 | 29 | 30 | 31 |
| Operating profit | $bn | 12 | - | ||||||
| Net profit | $bn | 0 | 6 | 5 | 6 | 0 | 9 | -3 | -1 |
| EPS reported | $ | 6.78 | -2.67 | ||||||
| Operating cashflow per share | $ | 8.05 | 10.90 | ||||||
| Capex per share | $ | 0.45 | 0.28 | ||||||
| FCF per share | $ | 7.60 | 10.62 | ||||||
| Free cash flow | $bn | 9 | 13 | ||||||
| Net debt | $bn | 15 | 23 | ||||||
| Book value equity | $bn | 23 | 12 | ||||||
| Book value per share | $ | 18.09 | 9.52 | ||||||
| Number of shares | m | 1,255 | 1,243 | ||||||
| DPS (TTM paid) | $ | 3.16 | 3.25 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 18.10 | - | ||||||
| P/B LTM | x | 6.73 | 12.91 | ||||||
| P/S LTM | x | 5.19 | 5.01 | ||||||
| P/FCF LTM | x | 16.15 | 11.57 | ||||||
| EV/EBITDA LTM | x | 12.52 | 267.39 | ||||||
| EV/Sales LTM | x | 5.78 | 6.40 | ||||||
| Earnings Yield LTM | % | +5.52% | -1.88% | ||||||
| FCF Yield | % | +6.19% | +8.64% | ||||||
| Quality | |||||||||
| ROE | % | +37.49% | -16.28% | ||||||
| ROIC | % | +20.32% | -3.66% | ||||||
| Operating margin | % | +39.74% | -4.90% | ||||||
| Gross margin | % | +78.83% | +79.59% | ||||||
| FCF/Sales | % | +32.12% | +43.34% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +1684.2% | - | ||||||
| Sales Growth YoY | % | +2.39% | +5.92% | ||||||
| Net Income Growth YoY | % | +1672.9% | - | ||||||
| FCF Growth | % | -8.24% | +28.08% | ||||||
| Operating Profit Growth | % | +604.03% | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +2.62% | +2.33% | ||||||
| Dividend Growth | % | +2.60% | +5.52% | ||||||
| Payout Ratio | % | +47.04% | -121.79% | ||||||
| FCF/Debt | x | 0.38 | 0.50 | ||||||
| Net Debt/EBITDA | x | 1.28 | 36.27 | ||||||
| EBIT/Net interest | x | 11.43 | -1.50 | ||||||
| Net debt/market cap | % | +16.33% | +15.28% | ||||||
| Net debt/Equity | x | 0.67 | 1.95 | ||||||
| Gross debt/equity | x | 1.10 | 2.22 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free